AbbVie Inc (ABBV) FY2025Q4 Earning Prediction
AbbVie Inc (ABBV) is set to release its FY2025Q4 earnings performance on 02/04 07:49:00 ET in Pre-Market trading. Consensus forecasts predict a revenue of 16.37B and an earnings per share (EPS) of 2.66 for the FY2025Q4. With Intellectia's exclusive AI algorithms, users can predict whether the earnings will beat or miss expectations before the report drops. Leverage this powerful tool to strategize and position your trades ahead of the earnings release!
AI Earnings Prediction
The earnings forecast predicts a 'Beat' due to strong performance in immunology and neuroscience segments, despite challenges in aesthetics.
Scenario Analysis
Key Indicators Forecast
No data
Prediction Logic & Rational
Logic & Justification
Fact Data Analysis Impacting Core Metrics:
- Immunology Growth (Skyrizi/Rinvoq):
Berenberg and Piper Sandler raised forecasts citing an "exceptional" growth outlook for Skyrizi and Rinvoq. HSBC highlighted that competition (e.g., Tremfya) is unlikely to materially threaten Skyrizi.
Impact: Likely revenue beat due to sustained high growth in immunology (~46% and 34% YoY) and expanded market penetration.
- Neuroscience Momentum (Vraylar/Migraine Portfolio):
Piper Sandler raised estimates for Neuroscience, noting underappreciated strength in Vraylar and AbbVie’s migraine drugs.
Impact: Potential revenue beat from continued 19.6% growth in neuroscience.
- Oncology Pipeline Progress:
- Positive Phase 3 results for epcoritamab (DLBCL trial) and RemeGen licensing deal ($650M upfront + milestone payments) signal pipeline strength. However, Venclexta growth may not fully offset Imbruvica declines in Q
- Impact: Neutral-to-slight beat for oncology (long-term upside, limited near-term revenue).
- Aesthetics Segment Challenges:
No material recovery signals in U.S. consumer sentiment or market conditions for aesthetics (down 4.2% last quarter).
Impact: Headwind to overall revenue growth.
- Free Cash Flow Strength:
$100B R&D/capital investment deal with the Trump administration and West Pharma facility acquisition ($175M) suggest operational efficiency. Skyrizi royalties ($13B generated in 9 months) remain robust.
Impact: EPS beat supported by cost controls and cash flow stability.
Tactical Strategy Recommendations
Trading Strategy
- Bullish Options Play: Buy $225–$230 calls expiring post-earnings (capitalize on upside from immunology/neuroscience beats).
- Pairs Trade: Long ABBV / Short aesthetics-exposed peers (e.g., ELAN, RVMD volatility).
- Hedge: Use protective puts if holding shares (mitigate risk of oncology/aesthetics disappointment).
Rationale: Market expectations are moderately priced (stock up 1.7% vs. S&P 1.2%), but immunology/neuroscience catalysts and cash flow stability tilt risk/reward favorably to a Beat.
Earnings Surprise Analysis
ABBV Transcript
The earnings call presents a positive outlook, with increased EPS guidance, revenue growth, and dividend hikes. Neuroscience and oncology show promising growth, and strategic investments in R&D and capital allocation support future prospects. Despite some pricing headwinds and market challenges, the overall sentiment remains positive, especially with strong guidance and shareholder returns.
AbbVie has raised its revenue and EPS guidance, indicating strong financial performance. Skyrizi and Rinvoq are expected to exceed guidance, and there is optimism in the neuroscience and immunology portfolios. Despite challenges in the aesthetics market and Humira erosion, the company anticipates growth driven by pipeline advancements and strategic acquisitions. The Q&A highlighted strong competitive positioning and market share gains. While some uncertainties remain, the overall sentiment is positive, suggesting a stock price increase in the short term.
ABBV Report
Frequently Asked Questions
What is the AbbVie Inc FY2025Q4 Earnings Release Date and Time?
AbbVie Inc (ABBV) is scheduled to release its FY2025Q4 earnings report onFeb 4, 2026, Pre-Market(approximately 4:00 PM ET). This timing allows investors to react during after-hours trading, with a conference call typically following shortly after.
What Are the Consensus Forecasts for AbbVie Inc FY2025Q4 Revenue and EPS?
Analysts' consensus predicts 16.37B in revenue and an EPS of 2.66 for AbbVie Inc's FY2025Q4.
What Does Intellectia's AI Predict for AbbVie Inc FY2025Q4 Earnings?
Intellectia's exclusive AI algorithms forecast a Beat forAbbVie Inc's FY2025Q4 earnings, with a prediction date of Feb 4, 2026. AbbVie Inc The earnings forecast predicts a 'Beat' due to strong performance in immunology and neuroscience segments, despite challenges in aesthetics.
How Can I Use This Earnings Prediction to Trade ABBV Stock?
Leverage Intellectia's AI forecast to position trades ahead of theFeb 4, 2026 release—consider calls for a beat scenario or protective puts for misses. Focus on pre-market volatility, and use the scenario probabilities to build strategies around revenue and guidance updates.
How Accurate Is Intellectia's AI for Earnings Predictions Like AbbVie Inc FY2025Q4?
Intellectia's predictions are backed by rigorous backtesting, showing a high hit rate for Beat and Miss calls compared to traditional analysis. While no forecast is 100% certain, we provide probability-based scenarios (e.g., 50% chance of a *Beat*) and detailed rationales to help you make informed decisions. Combine our insights with your strategy for the best results—it's like having a co-pilot for earnings season! Empowering users to strategize trades before reports drop.
How does AI Earnings Prediction generate its forecasts?
AI Earnings Prediction uses advanced Large Language Models (LLMs) to analyze a wealth of data, including past earnings transcripts, real-time market sentiment, analyst insights, and company news from the last three months. It focuses on key indicators like revenue, EPS, and margins to predict whether a company will *Beat*, *Miss*, or remain Neutral relative to market expectations. Think of it as a super-smart analyst crunching numbers and news 24/7 to give you a trading edge!
When are the predictions available, and how often are they updated?
Predictions are generated two days before a company’s earnings release (e.g., 5:00 PM ET on Feb 13 for a Feb 15 report) to capture the latest market and company data. They’re updated in real-time if significant news breaks, ensuring you get fresh insights.
Can I use AI Earnings Prediction for all types of stocks?
Currently, AI Earnings Prediction focuses on companies with market caps above $40 billion, covering major players like SPG, AAPL, MSFT, and NVDA for the 2025-2026 earnings seasons. We prioritize high-impact stocks with robust data to ensure reliable forecasts. Stay tuned as we expand coverage to more companies based on user demand!
